Eylea 8 mg approved in EU for 6-month dosing in nAMD and DME
EU expands Eylea 8 mg label to include longer intervals for nAMD and DME The European Commission (EC) has approved…
Perfuse Therapeutics Shares Promising Phase IIa Results in Glaucoma and Diabetic Retinopathy
Could better blood flow be the key to treating glaucoma and diabetic retinopathy? New findings suggest it just might. Sometimes…
latest posts
